Siemens Healthineers AG

Chart & Performance

D1W1MN

P/E

19.24

P/S

1.34

EPS

1.35

Div Yield, %

3.52%

Shrs. gr., 5y

—

Rev. gr., 5y

10.05%

Revenues

22.36b

+3.15%

Net income

1.94b

+28.69%

CFO

2.47b

+16.52%

Dividend

Apr 19, 20240.54974 USD/sh

Earnings

Jan 30, 2025

Profile

Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. It operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. The Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, and solutions and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services and consulting capabilities, and digital solutions and applications for managing treatment and therapy. The Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms, including a robotic-assisted platform for endovascular coronary and peripheral vascular interventions. It also provides equipment performance management, clinical education and e-learning, asset management, and managed departmental services for laboratories and healthcare facilities, as well as consulting and digital health services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.

URL

https://www.siemens-healthineers.com/

IPO date

Mar 16, 2018

Employees

70,800

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2024‑09	2023‑09	2022‑09	2021‑09	2020‑09	2019‑09	2018‑09	2017‑09	2016‑09	2015‑09
Income
Revenues	22,363,000 3.15%	21,680,000 -0.16%	21,714,000 20.65%
Cost of revenue	19,494,000	19,444,000	18,770,000
Unusual Expense (Income)
NOPBT	2,869,000	2,236,000	2,944,000
NOPBT Margin	12.83%	10.31%	13.56%
Operating Taxes	564,000	403,000	746,000
Tax Rate	19.66%	18.02%	25.34%
NOPAT	2,305,000	1,833,000	2,198,000
Net income	1,942,000 28.69%	1,509,000 -25.96%	2,038,000 18.01%
Dividends	(1,063,000)	(1,066,000)	(955,000)
Dividend yield	1.77%	1.96%	1.91%
Proceeds from repurchase of equity	(11,000)	(421,000)	(308,000)
BB yield	0.02%	0.78%	0.61%
Debt
Debt current	2,778,000	197,000	249,000
Long-term debt	13,455,000	1,028,000	1,133,000
Deferred revenue		12,711,000
Other long-term liabilities	1,269,000	301,000	14,587,000
Net debt	11,916,000	(695,000)	(347,000)
Cash flow
Cash from operating activities	2,469,000	2,119,000	2,504,000
CAPEX	(696,000)	(838,000)	(852,000)
Cash from investing activities	(666,000)	(1,069,000)	(868,000)
Cash from financing activities	(1,300,000)	(380,000)	(1,644,000)
FCF	(5,777,000)	6,591,000	1,631,000
Balance
Cash	2,912,000	1,766,000	1,598,000
Long term investments	1,405,000	154,000	131,000
Excess cash	3,198,850	836,000	643,300
Stockholders' equity	3,331,000	2,901,000	4,396,000
Invested Capital	32,551,150	23,697,000	33,567,700
ROIC	8.20%	6.40%	7.05%
ROCE	7.70%	8.54%	8.11%
EV
Common stock shares outstanding	1,116,092	1,123,552	1,127,746
Price	53.86 11.44%	48.33 8.75%	44.44 -20.76%
Market cap	60,112,713 10.70%	54,301,268 8.35%	50,117,032 -19.02%
EV	72,077,713	53,658,268	49,786,032
EBITDA	4,092,000	3,793,000	4,287,000
EV/EBITDA	17.61	14.15	11.61
Interest	476,000	296,000	118,000
Interest/NOPBT	16.59%	13.24%	4.01%